The SLC9A3 antibody targets the solute carrier family 9 member A3 (SLC9A3), a protein encoded by the SLC9A3 gene. This gene product, also known as sodium-hydrogen exchanger 3 (NHE3), is a transmembrane protein primarily expressed in the intestinal and renal epithelial cells. It regulates sodium absorption and pH homeostasis by exchanging intracellular protons for extracellular sodium ions. Dysregulation of SLC9A3 has been implicated in gastrointestinal disorders (e.g., congenital sodium diarrhea), cystic fibrosis-related complications, and hypertension, making it a focus in studies of electrolyte balance and epithelial transport mechanisms.
SLC9A3 antibodies are essential tools for detecting and quantifying NHE3 expression in research settings. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study protein localization, expression patterns, and functional alterations in disease models. Commercially available antibodies are typically raised against specific epitopes, such as the C-terminal or N-terminal regions, and validated for specificity using knockout controls or siRNA-mediated silencing. Researchers also employ these antibodies to explore SLC9A3’s role in pathological conditions, including metabolic acidosis, diabetic nephropathy, and inflammatory bowel disease. Recent studies highlight its interaction with signaling pathways (e.g., cAMP/PKA) and microbial toxins, emphasizing its therapeutic potential. Rigorous validation ensures minimal cross-reactivity with other NHE isoforms, enhancing reliability in experimental outcomes.